Identification of the new TAMC immune checkpoint, LAIR1, in patients with cancer and tumor-burdened mice provides an opportunity to determine a related pathway that links with TAM-induced tumor immunosuppression and helps to enhance endogenous multiplex immunity and adoptive cell therapy, such as CAR T cell therapy, against cancer. Here, LAIR1 is linked to cancer.